Royalty Pharma PLC (RPRX) to Issue Quarterly Dividend of $0.24 on March 10th

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, January 9th. Stockholders of record on Friday, February 20th will be given a dividend of 0.235 per share by the biopharmaceutical company on Tuesday, March 10th. This represents a c) dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Royalty Pharma’s previous quarterly dividend of $0.22.

Royalty Pharma has a dividend payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $4.86 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 19.3%.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $45.41 on Wednesday. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The business has a 50-day simple moving average of $40.68 and a 200 day simple moving average of $38.40. The stock has a market cap of $26.21 billion, a price-to-earnings ratio of 33.64 and a beta of 0.42. Royalty Pharma has a 52 week low of $29.66 and a 52 week high of $46.14.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The company had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. On average, research analysts forecast that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of research analyst reports. Leerink Partners set a $45.00 price target on Royalty Pharma in a report on Thursday, December 11th. Citigroup boosted their target price on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Friday, January 30th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Finally, Morgan Stanley restated an “overweight” rating and issued a $61.00 price objective on shares of Royalty Pharma in a report on Thursday, February 12th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $48.67.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.